The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
May. 10, 2016

Filed:

Oct. 01, 2013
Applicants:

Novo Norkisk A/s, Bagsværd, DK;

Innate Pharma S.a.s., Marseille, FR;

Inventors:

Peter Andreas Nicolai Reumert Wagtmann, Rungsted Kyst, DK;

Francois Romagne, La Ciotat, FR;

Joakim Glamann, Gentofte, DK;

Assignees:

Innate Pharma S.A.S., Marseilles, FR;

Novo Norkisk A/S, Bagsvaerd, DK;

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
C07K 16/28 (2006.01); C07K 16/08 (2006.01); A61K 39/395 (2006.01); A61K 45/06 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
A61K 39/3955 (2013.01); A61K 45/06 (2013.01); C07K 16/08 (2013.01); C07K 16/28 (2013.01); C07K 16/2803 (2013.01); C07K 16/2896 (2013.01); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01); C07K 2317/732 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01);
Abstract

Described are methods of treating viral disease using compounds that block inhibitory NK cell receptors, thereby reducing their inhibition of NK cell cytotoxicity in killing infected target cells. In one embodiment, the compound is an antibody binding, for example, one or more of the human KIR2DL1, KIR2DL2, and KIR2DL3 receptors. In another embodiment, the method further comprises administering a therapeutic antibody or fusion protein which binds an antigen expressed on cells infected with the virus.


Find Patent Forward Citations

Loading…